Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Nuvalent has reported phase 1/2 lung cancer data, teeing the biotech up to talk to the FDA about an approval filing that could establish its neladalkib as a challenger to Pfizer’s Lorbrena.

Akeso has a validated process in place for developing antibodies but does require US exposure to meet its lofty valuation.

The ASX healthcare sector ended the week ending November 21, 2025 down, following a sharp sell-off as on Wall Street and ...

UnitedHealth Group said on Tuesday it had named former U.S. Food and Drug Administration commissioner Scott Gottlieb to its ...

Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...

BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage ...

Gottlieb, who had served as the FDA chief from 2017 to 2019, stepped down abruptly in 2019 and joined the board of U.S.

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

The sliver of the FDA workforce that went offline during the government shutdown was back at their desks Thursday.

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...